TG THERAPEUTICS, INC. (TGTX) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
TG THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $7,781,000.00Increase in accounts payable and accrued expenses → Operating adjustments reconciliation: $65,347,000.00Stock-based compensation → Operating adjustments reconciliation: $27,875,000.00Decrease (increase) in other current assets → Operating adjustments reconciliation: $13,573,000.00Increase in deferred revenue → Operating adjustments reconciliation: $7,298,000.00Deferred income taxes → Operating adjustments reconciliation: $708,000.00Change in fair value of notes payable → Operating adjustments reconciliation: $524,000.00Noncash change in lease liability and right of use asset → Operating adjustments reconciliation: $441,000.00Amortization of debt issuance costs → Operating adjustments reconciliation: $247,000.00Depreciation and amortization → Operating adjustments reconciliation: $53,000.00Amortization of leasehold interest → Operating adjustments reconciliation: $43,000.00Operating adjustments reconciliation → Net cash from operating activities: $31,482,000.00Operating adjustments reconciliation → Increase in inventory: $66,824,000.00Operating adjustments reconciliation → Increase in accounts receivable: $9,519,000.00Operating adjustments reconciliation → Decrease in income taxes payable: $6,133,000.00Operating adjustments reconciliation → Change in fair value of equity investments: $1,227,000.00Operating adjustments reconciliation → Decrease in lease liabilities: $408,000.00Operating adjustments reconciliation → Decrease in other current liabilities: $262,000.00Operating adjustments reconciliation → Amortization of premium (discount) on investment securities: $254,000.00Proceeds from exercise of options → financing reconciliation: $85,000.00financing reconciliation → Net cash from financing activities: $85,000.00Proceeds from maturity of held-to-maturity securities → investing reconciliation: $17,750,000.00investing reconciliation → Net cash from investing activities: $1,030,000.00investing reconciliation → Investment in held-to-maturity securities: $16,427,000.00investing reconciliation → Purchases of property, plant and equipment: $293,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $443,561,000.00Net cash from operating activities → Cash sources and uses: $39,263,000.00Net cash from financing activities → Cash sources and uses: $85,000.00Net cash from investing activities → Cash sources and uses: $1,030,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $483,939,000.00Change in fair value of notes payable: $524,000.00Notes payable fair value+$524.00 KNoncash change in lease liability and right of use asset: $441,000.00Operating lease amortization+$441.00 KChange in fair value of equity investments: -$1,227,000.00Unrealized equity gain & loss−$1.23 MAmortization of leasehold interest: $43,000.00Leasehold interest amort.+$43.00 KDeferred income taxes: $708,000.00Deferred income taxes+$708.00 KAmortization of premium (discount) on investment securities: -$254,000.00Securities accretion, net−$254.00 KAmortization of debt issuance costs: $247,000.00Debt issuance cost amortization+$247.00 KDecrease in other current liabilities: -$262,000.00Other current liabilities−$262.00 KStock-based compensation: $27,875,000.00Stock-based compensation+$27.88 MIncrease in deferred revenue: $7,298,000.00Unearned revenue+$7.30 MDepreciation and amortization: $53,000.00Depreciation & amortization+$53.00 KNet income: $7,781,000.00Net income+$7.78 MIncrease in accounts payable and accrued expenses: $65,347,000.00Payables & accrued liabilities+$65.35 MDecrease in lease liabilities: -$408,000.00Operating lease liabilities−$408.00 KLoss on extinguishment of debt: $0.00Increase in accounts receivable: -$9,519,000.00Accounts receivable−$9.52 MDecrease in income taxes payable: -$6,133,000.00Income taxes payable−$6.13 MIncrease in inventory: -$66,824,000.00Inventories−$66.82 MDecrease (increase) in other current assets: $13,573,000.00Other current assets+$13.57 MNet cash from operating activities: $39,263,000.00Operating cash+$39.26 MOperating adjustments reconciliation: $116,109,000.00Payment of loan payable: $0.00Financing costs paid: $0.00Purchase of treasury stock: $0.00Proceeds from exercise of options: $85,000.00Stock option exercises+$85.00 KProceeds from debt financings, net of debt discount costs: $0.00Net cash from financing activities: $85,000.00Financing cash+$85.00 Kfinancing reconciliation: $85,000.00Purchases of property, plant and equipment: -$293,000.00PP&E purchases−$293.00 KInvestment in held-to-maturity securities: -$16,427,000.00HTM securities purchases−$16.43 MPurchases of equity investments: $0.00Proceeds from maturity of held-to-maturity securities: $17,750,000.00HTM securities maturities+$17.75 MNet cash from investing activities: $1,030,000.00Investing cash+$1.03 Minvesting reconciliation: $17,750,000.00Cash sources and uses: $483,939,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $443,561,000.00Beginning cash$443.56 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $483,939,000.00Ending cash$483.94 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$38.97 MOperating cash − cash spent on PP&ECash flow / Net income5.05×Operating cash flow ÷ net incomeNet cash change+$40.38 MEnding cash − beginning cash
Chart details

TG THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
443,561,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
39,263,000 US dollars. Net cash provided.
Net income
7,781,000 US dollars
Change in fair value of notes payable
524,000 US dollars
Noncash change in lease liability and right of use asset
441,000 US dollars
Change in fair value of equity investments
negative 1,227,000 US dollars
Amortization of leasehold interest
43,000 US dollars
Deferred income taxes
708,000 US dollars
Amortization of premium (discount) on investment securities
negative 254,000 US dollars
Amortization of debt issuance costs
247,000 US dollars
Decrease in other current liabilities
negative 262,000 US dollars
Stock-based compensation
27,875,000 US dollars
Increase in deferred revenue
7,298,000 US dollars
Depreciation and amortization
53,000 US dollars
Increase in accounts payable and accrued expenses
65,347,000 US dollars
Decrease in lease liabilities
negative 408,000 US dollars
Loss on extinguishment of debt
0 US dollars
Increase in accounts receivable
negative 9,519,000 US dollars
Decrease in income taxes payable
negative 6,133,000 US dollars
Increase in inventory
negative 66,824,000 US dollars
Decrease (increase) in other current assets
13,573,000 US dollars
Investing activities
1,030,000 US dollars. Net cash provided.
Purchases of property, plant and equipment
negative 293,000 US dollars
Investment in held-to-maturity securities
negative 16,427,000 US dollars
Purchases of equity investments
0 US dollars
Proceeds from maturity of held-to-maturity securities
17,750,000 US dollars
Financing activities
85,000 US dollars. Net cash provided.
Payment of loan payable
0 US dollars
Financing costs paid
0 US dollars
Purchase of treasury stock
0 US dollars
Proceeds from exercise of options
85,000 US dollars
Proceeds from debt financings, net of debt discount costs
0 US dollars
Operating adjustment reconciliation
116,109,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
85,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
17,750,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
483,939,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
483,939,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
40,378,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
5.05×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
39,263,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
293,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
38,970,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $31.48M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 39,263,000 US dollars minus 293,000 US dollars equals 38,970,000 US dollars.
TG THERAPEUTICS, INC. (TGTX) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!